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The transcription factor tumor protein p53 (TP53), frequently referred to as the "guardian of the genome", is ap ivotalt umor suppressor protein and mainstay of the body'sc ellular anticancer defense system. [1] TP53 is activatedf ollowing cellular stress and regulates multiple downstream target genes implicated in cell-cycle control, apoptosis, senescence and DNA repair. [2] The TP53 gene is mutated in about 50 %o fa ll human cancers whereas the other5 0% have tumors with TP53 wildtype status. [3] However,t he function of TP53 is frequently attenuatedi nt hese TP53 wild-type cancers by other mechanisms, including overexpression of its key negative regulator HDM2, which is the human homologue of moused ouble minute 2 (MDM2). Stabilizationa nd activation of TP53 by the inhibition of TP53 binding to its negative regulator MDM2 has been explored as an ovel approach to cancer therapy in patients with TP53 wild-type tumors.
[4] These research efforts have yielded several MDM2-p53 protein-protein interaction (PPI) inhibitors, which have been or are currently still being evaluated in early clinicaldevelopment.
[5]
High-grade thrombocytopenia wasr eported for several MDM2-p53i nhibitors as ad ose-limiting toxicity (DLT) in the clinic, in particular when testing continuous dose schedules. [5a, 6] To clinically managet hrombocytopenia, an ext generation of MDM2-p53i nhibitors with the potency and pharmacokineticp roperties to allow less-frequent dose schedules, [7] is needed. Our recentlyr eported MDM2-p53 inhibitor BI-0252( 1) resulted in tumor regressions in all animals of am ouse SJSA-1 xenograft study with as ingle, but high oral dose of 100 mg kg À1 .T od eliver ac ompound suitable to test less-frequent dose schedules in the clinic, we strived for further improvements in potency andp harmacokineticp roperties of our MDM2-p53inhibitors to decrease the required human dose on al ess-frequentd ose schedule. Herein we report the targeted syntheses of structurally complex and highly potent MDM2-p53 inhibitors with modified spiro-oxindole core structures, which were made accessible by employing unprecedented 1,3-dipolar cycloadditionc hemistry.
BI-0252 (1)i sa sachemically stable and orally active inhibitor of the MDM2-p53 interaction which bearsaspiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one core structure. [8] In contrast to the pioneering spiro[3H-indole-3,3'-pyrrolidin]-2(1H)-onesi nitially reported by Wang et al. (Scheme 1A) [9] and later by other groups, [10] which can undergo epimerization to four diastereomers via ar etro-Mannich/Mannich reaction in solution. [11] Additional spiro-oxindole MDM2 inhibitors include clinical candidate DS-3032b [12] and others. [13] The new class of spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-ones is not prone to this epimeri- zation. [8] The problem of epimerization was also recently addressedb yA guilar et al. leading to chemically stable inhibitors and the clinical candidate AA-115/APG-115, Scheme 1B. [14] The X-ray co-crystal structure of 1 in MDM2 (PDB ID:5 LAZ) revealed ah ydrogen bond between the basic secondary nitrogen of 1 and the side chain of His96 of the MDM2 protein as being important for the binding of 1 to MDM2 (Scheme 1C, Figure 2B ). [8] In contrast many other MDM2-p53 inhibitors address His96 with ac arbonyl oxygen functioning as hydrogen bond acceptor.
[11b] Striving for further potency optimization we aimed at evaluating the influence of replacing the secondary amine (hydrogen bond donor) by ac arbonyl group oxygen (hydrogen bond acceptor) in our lead series (Scheme 1D). To test this hypothesis we designed the five-membered lactam analogue 2 (NHt oC =O) and the six-membered lactam analogue 3 as close analogues of 1.
1,3-Dipolar cyclodadditions of azomethine ylides are av ersatile toolf or the generation of highly substituted pyrrolidines with dense stereochemistry.
[15] We took advantage of this powerful methodinour earlier study to generate the core structure of 1 by reacting 6-chloroisatin,1 -(2-fluoro-3-chlorophenyl)-2-nitroethenea nd l-homoserine in at hree-component reaction. [8] For the synthesis of the new core structures the use of an intermolecularc ycloaddition seemedl ess attractive, as published reports suggestt hat the outcome of such reactions using substituteds tyrene analoguesa sd ipolarophiles with electronwithdrawing groups other than an itro group would favor an undesired regioisomer. [16] We therefore envisioned an intramolecular cycloaddition whichs hould favor the desired regioisomer.
Intramolecular cyclodadditions of azomethine ylides have been used successfully to generate complex fused pyrrolidine, dihydropyrrole or pyrrole ring systemsa nd are particularly valuable for the synthesis of natural products.
[17] Marx et al. reported the usefulness of this method to generate novel polycyclic lactams for the design of screening libraries (Scheme 2A) and therein describes the reaction of isatin with 2-(methylami-
'-dione compound with undetermined stereochemistry in moderate yield. [18] To access the desired unprecedented octahydro-1'Hspiro[indole-3,2'-pyrrolo[2,3-c]pyrrole]2,4'-dione core structure we planned to modify the amine components to 2-amino-3-(prop-2-enamido)propanoic acids and 2-amino-3-(prop-2-enamido)butanoic acids (Scheme 2B), which should readily generate the azomethine ylide after imine formation with an isatin analogue followed by subsequent decarboxylation. The ylide was expected to react with the remaining doubleb ond to yield the desired product.
We startedt he synthesis by preparing the amino acid cyclization precursors 9 and 10 (Scheme 3) from commercially available3 -amino-N-(tert-butoxycarbonyl)-l-alanine tert-butyl ester (5)a nd (S)-2-tert-butoxycarbonylamino-4-aminobutyric acid tert-butyle ster (6)b ya mide coupling with (2E)-3-(3-chloro-2-fluorophenyl)prop-2-enoic acid (4). Both reactions proceeded in close to quantitative yields to give compounds 7 and 8.T or emove the Boc and tert-butyl protecting groups, compounds 7 and 8 were treated with trifluoroacetic acid in CH 2 Cl 2 at RT,a nd after completiono ft he reactions amino acids 9 and 10,r espectively,w ere precipitated from water at pH 6-7 in excellent yields. With the cyclization precursors 9 and 10 now in hand, we performed the first decarboxylative cycloaddition by heating 9 with one equivalent of 6-chlorisatin (11)i n methanola t1 00 8Cf or 30 min in am icrowaver eactor. [19] We were able to isolate an inseparable mixtureo ft he diastereomers rac-12 a and rac-12 b in 23 %y ield and ad iastereomeric ratio of 1:3. After reductivea mination of this mixture with cyclopropylcarboxaldehyde we were able to isolate rac-13 in quantitative yield based on the content of rac-12 a which was separatedb yc hiral SFC to obtain enantiomerically pure 13. Buchwald couplingw ith methyl 4-bromobenzoate (14)a nd subsequents aponification delivered target compound 2.D espite the low yield and unfavorable selectivity in the cycloaddition step we were able to obtain the complex polycyclic structure of 2 in only six synthetic steps to obtain sufficient material for biological testing.
For the synthesis of the six-membered lactam analogue 3 we reactedt he cyclization precursor 10 with one equivalent of 11 under the same conditions and isolated the two diastereomers rac-15 a and rac-15 in ayield of 61 %f avoring the desired compound rac-15 a (d.r. = 1.7:1). Reductivea minationo frac-15 a with cyclopropylcarboxaldehyde and subsequentc hiral SFC separation gave compound 16.B uchwald coupling of lactam 16 with methyl 4-bromobenzoatea nd saponification deliveredc ompound 3 in good overall yields (Scheme 3).
To test whether the highery ield for the ylide intermediate 10 (n = 2) versus 9 (n = 1) is due to pre-organization we explored their conformational ensemblesu sing af ine-grained systematic conformational search in MOE 2016.0802 (Figure 1) . We enumerated accessible conformations in an energy window of 10 kcal mol À1 with am inimum pair-wise RMSD of 0.1 using the default AMBER10:EHT force field alongw ith a dielectric constant of 32.7 resemblingm ethanol. Resulting conformationsw eres ubsequently energy minimized on B3LYP-D3/ 6-31G* level in implicit methanol solvation using Gaussian 09. [20] Resulting conformationsw ere analyzedw ith respect to their compactnessu sing the radius of gyration r gyr as well as with respectt ot heir RMSD to modelled intermediate conformations leadingt odesired and undesired reaction products. Superposition of 1 (white) and 13 (grey) extracted from crystal structures of MDM2 ligand complexes(PDB IDs:5LAZ and 6I3S) with lowenergyc onformation for linker length n = 1( green) and the lowest-energy conformation for n = 2( cyan). We find ap reorganization of the reaction educts in solution allowinga nintramolecular cycloaddition starting from low-energy conformations. For both linker lengths we found al arge set of collapsed conformations within the respective ensemble that are pre-organized for an intramolecular cycloaddition. For n = 1w e found 60 of 175 total conformations (34 %) with r gyr < 4 which typicallyi ndicates stackingi nteractions between both psystemsi nt he ylide intermediate. For the molecule with linker length n = 2, we similarly found 57 of 148 conformations with r gyr < 4 (39 %). For compounds with n = 1c ollapsed conformations do not directly correspond to the minimum energy conformations but are very close with as train energy of only + 0.7 kcal mol À1 .E longating the linkaget on = 2f ocusses the conformational ensemble specifically around the collapsed form. The lowest non-collapsed conformation is strongly unfavorable and only found at + 6.5 kcal mol À1 in the latter case. These findings are consistent with the higher reaction yields obtainedf or educts with linker length n = 2. In addition to the formation of pre-organized collapsed conformations of the ylide intermediates,w ef ound af ocusing of the conformationsa rounds tructures leadingt os pecific diastereomeric reactionp roducts. Amongst all conformationsw ith r gyr < 4 precursor conformations locking the lactam 5-ring in the undesired direction are found more often (60 %) than in the desired conformation (40 %). For the larger intermediates leading to the lactam 6-ring product we found only 51 %o fc onformationsp re-organized to form the undesired diastereomer versus4 9% for the desired one. Both, dominance of the precursor to the undesired product for the 5-ring lactama sw ell as an almost equal distribution of precursor conformations for the 6-ring lactam are in line with the observed syntheses yields.
To evaluate the influence of replacing the secondary amine (hydrogenb ond donor) by ac arbonyl group (hydrogen bond acceptor) we measured biochemical( IC 50 (MDM2-p53)) anda lso the cellular potency in the p53 wild-type osteosarcoma SJSA-1 cell line proliferation assay (Table1). Like 1,c ompounds 2 and 3 showedl ow nanomolar potency in the MDM2-p53 assay (4 nm)w hich is at the assay-wall of this assay.W eo bserved a significant improvement in the cellular potency when comparing compound 1 (471 nm)a nd the new five-membered lactam compound 2 (161 nm)w hilet he six-membered lactam analogue 3 showedp otency similart o1.T his showedt hat for our spiro-oxindole cores tructure compounds addressing His96 MDM2 with ac arbonyl oxygen (hydrogen bond acceptor) are favored in terms of potency. To assess off-target selectivity we tested compounds 2 and 3 against the p53 mutant cell line SK-OV-3 which showed no effect on the growth of the p53 mutantS K-OV-3 cell line up to ac oncentration of 25 mm.T his indicates that compounds 2 and 3 are selectiveM DM2-p53 PPI inhibitors similar to the data reportedf or 1.
An X-ray crystal structure of compound 13 in MDM2 (Figure 1A) s howed that the lactam carbonyl indeedf orms ah ydrogen bond interaction with the side chain of His96 MDM2 .T he overlay of the structure with the X-ray crystal structure of compound 1 (PDB ID:5 LAZ) shows av ery similar bindingm ode with compound 13 slightly shiftedt oe nable hydrogen bond formation with His96 MDM2 (Figure 2 ).
In conclusion, we have developed an unprecedentedi ntramolecular cyclization of azomethine ylides which enabled access to octahydropyrrolo [2,3-c] pyrrol-4-onesa nd octahydropyrrolo[2,3-c]pyridine-4-ones anda llowedt he targeted synthesis of structurally complex and highly functionalized spiro-oxindoles 2 and 3 in highlye fficient 6-steps sequences. We investigated the pre-organization of the ylide intermediates of the cycloaddition reaction to rationalize the outcome of the experiments by computational methodsw hich could facilitate future synthesis planning of intramolecular cycloadditions. The compoundsw ere prepared to investigate the effect of introducing ah ydrogen bond acceptor (lactam carbonyl oxygen) to our spiro-oxindole MDM2-p53 PPI inhibitors to addresst he sidechain of His96 MDM2 in comparison with the earlier compound BI-0252(1)w hich carriedahydrogen bond donor at an equivalent position. Compound 2 displayed at hreefold improvement in potency in the p53 wild-type osteosarcoma SJSA-1c ell line proliferation assay relative to 1.This findingg uided our optimization efforts towardh ydrogen bond acceptors at this position and wasa ni mportant milestone towardaMDM2-p53P PI in- hibitor suitable to test less frequent dose schedulesw ith the intentiont om anage thrombocytopeniai nt he clinic. In vivo profiling of 2 and additional compounds will be reported in due course.
